for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Verrica Pharmaceuticals Inc

VRCA.OQ

Latest Trade

6.66USD

Change

-0.18(-2.63%)

Volume

63,739

Today's Range

6.55

 - 

6.98

52 Week Range

6.18

 - 

18.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.84
Open
6.98
Volume
63,739
3M AVG Volume
2.66
Today's High
6.98
Today's Low
6.55
52 Week High
18.67
52 Week Low
6.18
Shares Out (MIL)
25.81
Market Cap (MIL)
176.57
Forward P/E
-3.81
Dividend (Yield %)
--

Latest Developments

More

Verrica Pharmaceuticals Reports Q2 2020 Financial Results

Verrica Pharmaceuticals Receives Complete Response Letter From The FDA For New Drug Application For VP-102

Verrica Pharmaceuticals Provides Regulatory Update On VP-102

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Industry

Biotechnology & Drugs

Contact Info

10 N High St Ste 200

WEST CHESTER, PA

19380-3014

United States

+1.484.4533300

http://www.verrica.com/

Executive Leadership

Paul B. Manning

Chairman of the Board

Ted W. White

President, Chief Executive Officer, Director

Brian Davis

Chief Financial Officer

Christopher G. Hayes

General Counsel, Corporate Secretary, Chief Legal Officer

Joe Bonaccorso

Chief Commercial Officer

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.410

2019

-1.130

2020(E)

-1.656
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
60.83
LT Debt To Equity (MRQ)
60.83
Return on Investment (TTM)
-35.10
Return on Equity (TTM)
-33.87

Latest News

Latest News

BRIEF-Verrica Pharmaceuticals Provides Regulatory Update On VP-102

* VERRICA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON VP-102

BRIEF-Verrica Pharmaceuticals Announces Positive Results From Two New Pooled Analyses Of Phase 3 CAMP Trials Of VP-102

* VERRICA PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM TWO NEW POOLED ANALYSES OF THE PHASE 3 CAMP TRIALS OF VP-102 IN MOLLUSCUM CONTAGIOSUM

BRIEF-Verrica Pharmaceuticals Reports Qtrly Net Loss Per Share $0.39

* VERRICA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Verrica Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million

* VERRICA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source: (http://bit.ly/38LTG6M) Further company coverage:

BRIEF-Verrica Pharmaceuticals Reports Q4 Loss Per Share Of $0.31

* VERRICA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

BRIEF-Verrica Pharmaceuticals Secures $55 Mln In Loan Facilities

* VERRICA PHARMACEUTICALS SECURES $55 MILLION IN LOAN FACILITIES LED BY SILICON VALLEY BANK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up